DC
CEMI

Diametric Capital’s Chembio diagnostics, Inc. CEMI Stock Holding History

Diametric Capital’s Portfolio CEMI Stock Details CEMI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q3 		– Sell
-76,893
Closed -$250K – 232
2020
Q2 		$250K Buy
+76,893
New +$730K 0.19% 110

Other funds holding CEMI

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
SBH
Segall Bryant & Hamill Chicago, Illinois $6.98B AUM 34.78% 1-Year Est. Return
RA
Royce & Associates New York $10.1B AUM 42.88% 1-Year Est. Return
PM
Penbrook Management New York $157M AUM 46.57% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
N
Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return

Diametric Capital's CEMI Position: Q3 2020 in Review

Diametric Capital sold out of Chembio diagnostics, Inc. (CEMI) in Q3 2020, closing a stake of 76,893 shares — an estimated $250K sold.

Diametric Capital first reported a position in CEMI in Q2 2020 and held it in 1 quarter. The position peaked at $250K in Q2 2020. 59 funds tracked by Wall St. Rank hold CEMI as of Q3 2020.

  • Diametric Capital reported no remaining Chembio diagnostics, Inc. position as of Q3 2020 after selling out during the quarter.
  • Diametric Capital sold 76,893 Chembio diagnostics, Inc. shares in Q3 2020, an estimated $250K.
  • Diametric Capital first reported a position in Chembio diagnostics, Inc. in Q2 2020 and held it in 1 quarter.
  • Diametric Capital's Chembio diagnostics, Inc. position peaked at $250K in Q2 2020.
  • 59 funds tracked by Wall St. Rank held Chembio diagnostics, Inc. as of Q3 2020.

Based on Diametric Capital's 13F filing for Q3 2020, filed 13 Nov 2020.